Moreover, the recent FDA approval of the HDAC inhibitor panobinostat to treat advanced multiple myeloma [20] highlights the feasibility of developing a BET–HDAC inhibitor combination strategy in the clinic. The gene discussed is DNER; the disease is plasma cell myeloma.